Mavrilimumab
- Product Name
- Mavrilimumab
- CAS No.
- 1085337-57-0
- Chemical Name
- Mavrilimumab
- Synonyms
- CAM 3001;Mavrilimumab;Mavrilimumab (anti-CD116);Research Grade Mavrilimumab;Research Grade Mavrilimumab(DHD11501)
- CBNumber
- CB48080815
- Formula Weight
- 0
- MOL File
- Mol file
Mavrilimumab Property
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Mavrilimumab Chemical Properties,Usage,Production
Uses
Mavrilimumab (CAM-3001) is an investigational human IgG4 monoclonal antibody (MAb) targeting GM-CSF receptor alpha which is currently being developed for the treatment of RA. GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils.
in vivo
Mavrilimumab (3–100 mg/kg, intravenously, once weekly for at least 11 weeks) inhibits GM-CSF signalling. Prolonged high-dose administration may induce neutrophilic lipid deposition, foam cell formation, cholesterol clefts, and granulomatous inflammation in alveolar macrophages. Mavrilimumab exhibits immunogenicity in crab-eating macaques, with repeated administration inducing anti-drug antibodies that accelerate drug clearance and reduce exposure levels[2].
| Animal Model: | Cynomolgus monkey models [2] |
| Dosage: | 3–100 mg/kg |
| Administration: | intravenous, once weekly for at least 11 weeks |
| Result: | Produced foam cells in the lungs. |
Mavrilimumab Preparation Products And Raw materials
Raw materials
Preparation Products
Mavrilimumab Suppliers
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 57505
- Advantage
- 58